Get the Stockscreener App
2.26
0.44%
-0.01
After Hours:
2.27
0.01
+0.44%
Xbiotech Inc stock is traded at $2.26, with a volume of 30,061.
It is down -0.44% in the last 24 hours and down -3.00% over the past month.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
See More
Previous Close:
$2.27
Open:
$2.26
24h Volume:
30,061
Relative Volume:
0.92
Market Cap:
$68.90M
Revenue:
$300.00K
Net Income/Loss:
$-40.16M
P/E Ratio:
-1.7155
EPS:
-1.3174
Net Cash Flow:
$-42.36M
1W Performance:
+0.44%
1M Performance:
-3.00%
6M Performance:
-16.61%
1Y Performance:
-21.25%
1-Day Range:
$2.25
$2.27
1-Week Range:
$2.19
$2.31
52-Week Range:
$2.09
$3.61
Xbiotech Inc Stock (XBIT) Company Profile
Name
Xbiotech Inc
Sector
Industry
Phone
512-386-2900
Address
5217 WINNEBAGO LANE, AUSTIN, TX
Compare XBIT vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XBIT
Xbiotech Inc
|
2.26 | 69.21M | 300.00K | -40.16M | -42.36M | -1.3174 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Xbiotech Inc Stock (XBIT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-14-19 | Initiated | Piper Jaffray | Overweight |
| Apr-21-17 | Downgrade | Noble Financial | Buy → Hold |
| Jun-28-16 | Reiterated | Noble Financial | Buy |
Xbiotech Inc Stock (XBIT) Latest News
XBiotech Inc (XBIT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
XBiotech Inc (XBIT) Balance Sheet - TradingKey
XBIT|XBiotech Inc|Price:2.260|Chg%:-0.010 - TradingKey
XBiotech Inc (XBIT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
XBiotech Inc (XBIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
XBIT|XBiotech Inc|Price:2.270|Chg%:-0.010 - TradingKey
XBiotech, Inc. Actuals & Estimates (FWB:4XB) - TradingView
XBiotech Inc (XBIT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
XBiotech Inc. Revenue Breakdown – NASDAQ:XBIT - TradingView
MSN Money - MSN
XBiotech (XBIT) Holds Steady at $2.29 as Range-Bound Trading ContinuesIPO Entry Watch - dars.gov.et
XBiotech Inc. (XBIT) Slides 2.97% as Shares Approach Key Support at $2.18Pairs Trade - dars.gov.et
XBiotech focuses on antibody pipeline as biotech sector evolves - Ad-hoc-news.de
ETFs Investing in XBiotech, Inc. Stocks - TradingView
XBiotech, Inc. Actuals & Estimates (SWB:4XB) - TradingView
XBiotech Inc. (XBIT) Holds Steady at $2.33 as Key Support and Resistance Levels ConvergeVolume Dry Up - dars.gov.et
XBiotech, Inc. Actuals & Estimates (LS:A14QF1) - TradingView
XBiotech, Inc. Actuals & Estimates (MUN:4XB) - TradingView
Price to earnings forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (NASDAQ:XBIT) - TradingView
Price to sales forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (DUS:4XB) - TradingView
XBiotech, Inc. Actuals & Estimates (BX:4XB) - TradingView
Enterprise value to revenue forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech, Inc. Actuals & Estimates (BOATS:XBIT) - TradingView
Price to book forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
Enterprise value to EBIT forward of XBiotech Inc. – NASDAQ:XBIT - TradingView
XBiotech to commence V-SPINE trial enrolment for vilamakitug - MSN
XBiotech (XBIT) Dips 2.53% as Shares Test Support Near $2.19Motive Wave - dars.gov.et
XBiotech Inc. (XBIT) Nears Key Support After 2.5% DeclineAdvance Decline Volume - dars.gov.et
XBiotech Inc. (XBIT) Declines: Testing Key Support Levels After 2.53% DropHigh Beta Stocks - dars.gov.et
XBiotech Inc (XBIT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
XBiotech Inc (XBIT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
XBiotech Inc (XBIT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
XBiotech Inc (XBIT) Valuation: PE, PB & Fair Value Analysis - TradingKey
XBiotech Inc (XBIT) Institutional Confidence - TradingKey
XBIT Earnings Overview 2026-06-16Profit Warning Alert - dars.gov.et
XBiotech Receives Authorization for V-SPINE Trial - Intellectia AI
XBiotech Inc Stock (US9840001002): FDA clears Phase II V-SPINE trial for vilamakitug in axial spondy - AD HOC NEWS
XBiotech (XBIT) Receives FDA Nod for V-SPINE Study - GuruFocus
XBiotech clears FDA review for axial spondyloarthritis study - Investing.com
XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis - Yahoo Finance UK
XBiotech Inc. (XBIT) Holds Near Support Amidst Minor DeclinesDescending Triangle - newsline.com
XBIT Should I Buy - Intellectia AI
XBiotech Inc stock (US9840001002): shares little changed as investors await next earnings update - Ad-hoc-news.de
XBiotech Inc. (XBIT) Slips 2.27% as Stock Tests Key Support LevelsMotive Wave - The Legal Advocate
XBITXBiotech Inc Dividends - Finviz
XBiotech Inc. (XBIT) Edges Higher, Approaching Key Resistance at $2.56Trading Ideas - The Legal Advocate
XBiotech Inc. (XBIT) Edges Higher on Modest Volume, Tests Resistance Near $2.58Composite Profile - The Legal Advocate
XBiotech (XBIT) Edges Lower as Stock Tests Key Support LevelFloat Adjusted Cap - dars.gov.et
XBIT | XBiotech Inc Insider Trading - Quiver Quantitative
Xbiotech Inc Stock (XBIT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):